Janssen-Cilag and Furiex Publications

  1. Broad Spectrum In Vitro Activity of JNJ-Q2, a New Fluoroquinolone. Poster F1-2033 presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting held in Washington, D.C. October 25-28, 2008. Authors: Barbara Foleno, Brian Morrow, Ellyn Wira, Mark Macielag and Karen Bush.
  2. In Vitro Staphylococcus Aureus Activities and Resistance Selection in MRSA with the New Fluoroquinolone JNJ-Q2. Poster F1-2035 presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting held in Washington, D.C. October 25-28, 2008. Authors: Wenping He, Karen Amsler, Karen Bush and Brian Morrow.
  3. In Vitro Activity of JNJ-Q2, a New Fluoroquinolone, against Susceptible and Multi-Drug Resistant Streptococcus Pneumoniae. Poster F1-2052 presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting held in Washington, D.C. October 25-28, 2008. Authors: Brian Morrow, Barbara Foleno, Raul Goldschmidt, Wenping He, Karen Amsler, Mark Macielag and Karen Bush.
  4. Antistaphylococcal Activity of JNJ-Q2, a New Type II Topoisomerase Inhibitor. Poster F1-1979 presented at the 49th Annual ICAAC Meeting held in San Francisco, Calif. September 2009. Authors: Cynthia D. Todd, Lois M. Ednie, Klaudia Kosowska-Shick and Peter C. Appelbaum.
  5. In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone. Antimicrobial Agents and Chemotherapy, May 2010, p. 1955–1964 Vol. 54, No. 5. Authors: Brian J. Morrow, Wenping He, Karen M. Amsler, Barbara D. Foleno, Mark J. Macielag, A. Simon Lynch and Karen Bush.
  6. Inhibition of S. aureus DNA Gyrase and DNA Topoisomerase IV Enzymes by the New Fluoroquinolone JNJ-Q2. Poster F1-2090 presented at the 50th Annual ICAAC/IDSA Meeting held in Boston, MA September 12-15, 2010. Authors: A.M. Queenan, W. Shang, T.A. Davies, and A.S. Lynch.
  7. Comparative Resistance Selection in Methicillin-Resistant Staphylococcus Aureus(MRSA) During Serial Passage Studies Conducted with Ciprofloxacin (CIP) or the New Fluoroquinolone JNJ-Q2. Poster F1-2091 presented at the 50th Annual ICAAC/IDSA Meeting held in Boston, MA September 12-15, 2010. Authors: B. Morrow, E. Baum, S. Crespo-Carbone, W. He, K.M. Amsler and A.S. Lynch.
  8. Activity of a New Fluoroquinolone JNJ-Q2 and Comparators in an In vitro Staphylococcus aureus Biofilm Model. Poster F1-2092 presented at the 50th Annual ICAAC/IDSA Meeting held in Boston, MA September 12-15, 2010. Authors: D. Abbanat, C. Santoro and A.S. Lynch.
  9. Efficacy of a New Fluoroquinolone (FQ) JNJ-Q2 in Murine Models of Staphylococcus Aureus and Streptococcus pneumonia Infection. Poster F1-2093 presented at the 50th Annual ICAAC/IDSA Meeting held in Boston, MA September 12-15, 2010. Authors: J. Fernandez, J.J. Hilliard, J.L. Melion, B.J. Morrow, R.K. Flamm and A.S. Lynch.
  10. JNJ-Q2 – A New Broad Spectrum Fluoroquinolone. Session 243: New Inhibitors of DNA Replication. Wednesday, September 15, 2010 at the 50th Annual ICAAC/IDSA Meeting held in Boston, MA September 12-15, 2010. Presented by Brian Morrow.
  11. JNJ-Q2 – A New Fluoroquinolone with Potent in Vitro Activity Against Staphylococcus aureus, including Methicillin- and Fluoroquinolone-resistant strains. Poster LB-3 presented at the 48th Annual IDSA Meeting held in Vancouver, BC, Canada October 21-24, 2010. Authors: D.J. Farrell, L.C. Liverman, D.J. Biedenbach, R.N. Jones.
  12. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2010) European pathogens isolated from patients with community-acquired bacterial pneumonia. Poster 1137 presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the International Congress of Chemotherapy (ICC) held in Milan, Italy May 7-10, 2011. Authors: D.J. Farrell, L.C. Liverman, P.R. Rhomberg, R.N. Jones.
  13. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2010) European pathogens isolated from patients with acute bacterial skin and skin structure infections. Poster 1138 presented at the 2011 joint meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the International Congress of Chemotherapy (ICC) held in Milan, Italy May 7-10, 2011. Authors: D.J. Farrell, L.C. Liverman, P.R. Rhomberg, R.N. Jones.
  14. JNJ-Q2, a New Fluoroquinolone with Potent In Vitro Activity against Staphylococcus aureus, Including Methicillin- and Fluoroquinolone-Resistant Strains. Antimicrobial Agents and Chemotherapy, July 2011, p. 3631–3634 Vol. 55, No. 7. Authors: D.J. Farrell, L.C. Liverman, D.J. Biedenbach and R.N. Jones.
  15. Determination of Disk Diffusion and MIC Quality Control Guidelines for JNJ-Q2, a Novel Quinolone.  Journal of Clinical Microbiology, August 2011, Vol. 49, No. 48, p. 3009-3011.  Authors:  J.E. Ross, L.C. Liverman and R.N. Jones.
  16. Evaluation of Single and Repeat Dose Pharmacokinetics, Accumulation, Absolute Bioavailability and Safety of JNJ-Q2.  Poster presented at the 40th Annual ACCP Meeting held in Chicago, IL September 11-13, 2011.  Authors:  J.M. Davenport, P.C. Covington, G. McIntyre, J. Almenoff and L.C. Liverman.
  17. Studies of the Efficacy of a New Fluoroquinolone, JNJ-Q2, in Skin, Respiratory, and Systemic Murine Models of Staphylococcus aureus and Streptococcus Pneumoniae Infection. Published online ahead of print in Antimicrobial Agents and Chemotherapy, September 12, 2011.  Authors:  J. Fernandez, J.J. Hilliard, B.J. Morrow, J.L. Melton, R.K. Flamm, A.M. Barron and A.S. Lynch.  http://www.ncbi.nlm.nih.gov/pubmed/21911568
  18. Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2.  Published online ahead of print in Antimicrobial Agents and Chemotherapy, September 12, 2011.  Authors:  B.J. Morrow, D. Abbanat, E.Z. Baum, S. M. Crespo-Carbone, T.A. Davies, W. He, W. Shang, A.M. Queenan and A.S. Lynch.  http://www.ncbi.nlm.nih.gov/pubmed/21911562 
  19. Activity of JNJ-Q2, a New Fluoroquinolone, Tested Against Contemporary Pathogens Relevant to Acute Bacterial Skin and Skin Structure Infection (ABSSSI).  Poster C2-1794 presented at the 51st Annual ICAAC Meeting held in Chicago, IL September 17-20, 2011.  Authors:  D.J. Farrell, L.C. Liverman, P.R. Rhomberg and R.N. Jones. 
  20.  Activity of JNJ-Q2, a New Fluoroquinolone, Tested Against Contemporary Pathogens Isolated from Patients with Community-Acquired Bacterial Pneumonia.  Poster C2-1795 presented at the 51st Annual ICAAC Meeting held in Chicago, IL September 17-20, 2011.  Authors:  D.J. Biedenbach, L.C. Liverman, R.N. Jones and D.J. Farrell.
  21. A Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared With Linezolid (Zyvox®) for the Treatment of Acute Bacterial Skin and Skin Structure Infection.  Published online ahead of print in Antimicrobial Agents and Chemotherapy, September 26, 2011.  Authors:  P.S. Covington, J.M, Davenport, D. Andrae, W. O'Riordan, L.C. Liverman, G. McIntyre and J.S. Almenoff.  http://aac.asm.org/cgi/reprint/AAC.05044-11v1
  22. Activity of JNJ-Q2, a Novel Fluoroquinolone, Tested against Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Strains.  Poster 612 presented at the 49th Annual IDSA Meeting held in Boston, MA October 20-23, 2011.  Authors:  D.J. Biedenbach, J.S. Almenoff, R.R. Prochaska, R.N. Jones and D.J. Farrrell.
  23. Activity of JNJ-Q2 and Comparators against Genetically Defined MRSA Clones.  Poster 598 presented at the 49th Annual IDSA Meeting held in Boston, MA October 20-23, 2011.  Authors:  D.J. Farrell, L.C. Liverman, R.E. Mendes, D.J. Biedenbach and R.N. Jones.